Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1749-4486.2011.02333.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The p16 Immunostaining Predicts the Risk of Recurrence in Prostate Cancer.
Asian Pac J Cancer Prev
January 2025
Postgraduate Program in Oncology, Haroldo Juaçaba Hospital, Ceará Cancer Institute (ICC), Brazil.
Objective: This study aimed to investigate the influence of p16 immunohistochemical expression on the biochemical recurrence rate of pT2-pT3 prostate cancer.
Materials And Methods: A total of 488 pT2-pT3 stage prostate adenocarcinomas undergoing radical prostatectomy were included in this study. Following a review of Gleason classification and retrieval of sociodemographic and clinicopathological data, as well as the date of last consultation and biochemical recurrence, immunohistochemistry for p16 was performed.
Evaluating C-Reactive Protein and Procalcitonin Discordance Among Febrile Infants at Risk of Serious Bacterial Infections.
Acta Paediatr
January 2025
Department of Emergency Medicine, KK Women's and Children's Hospital, SingHealth-Duke NUS Paediatrics Academic Clinical Programme, Duke-NUS Medical School, Singapore.
Aim: We aimed to investigate the prevalence and factors associated with C-reactive protein (CRP) and procalcitonin (PCT) discordance in febrile infants with serious bacterial infections (SBIs).
Methods: We performed a retrospective review of febrile infants ≤ 90 days old presenting to the emergency department between December 2018 and June 2023. We compared conservative and pragmatic thresholds for PCT (< 0.
Inavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFHighly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.
Ann Nucl Med
January 2025
Department of Radiological Sciences, School of Health Science, Fukushima Medical University, 10-6 Sakae, Fukushima City, Fukushima, 960-8516, Japan.
Objective: This study aims to accurately classify ATN profiles using highly specific amyloid and tau PET ligands and MRI in patients with cognitive impairment and suspected Alzheimer's disease (AD). It also aims to explore the relationship between quantified amyloid and tau deposition and cognitive function.
Methods: Twenty-seven patients (15 women and 12 men; age range: 64-81 years) were included in this study.
The role of different health information sources in moderating the impact of health literacy on health-related quality of life: evidence from a population-based study in Korea.
Qual Life Res
January 2025
College of Nursing, Seoul National University, Seoul, 03080, South Korea.
Purpose: Health literacy is a key aspect of healthy living and is widely recognized as a crucial determinant of health outcomes and disparities. Health literacy enables individuals to make informed decisions by accessing, understanding, and utilizing health-related information effectively. Access to and use of health information are essential for optimal health outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!